TrialBreast cancer research and treatment2021

Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations.

Yi-Zhou Jiang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.